{
    "nct_id": "NCT04294576",
    "official_title": "First-in-human (FIH), Open-Label, Phase 1a (Dose Escalation)/Phase 1b (Expansion Cohort) Trial of BJ-001 as a Single Agent and in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Solid Tumors",
    "inclusion_criteria": "* Phase 1a patients must have locally advanced or metastatic solid tumors,\n* Phase 1b patients must have locally advanced or metastatic and/or non-resectable head and neck squamous cell carcinoma, cholangiocarcinoma, stomach cancer, melanoma, pancreatic cancer, NSCLC (as high expression of αVβ3, αVβ5, or αVβ6 have been reported for these tumors)\n\n  * Measurable disease: For Phase 1a patients can have non-measurable or measurable disease. For all other parts: measurable disease defined by RECIST v1.1 is required\n  * For Phase 1a Part 3 and Phase 1b patients (combination treatment) must be refractory or relapsed to anti-PD-1, anti-PD-L1 or anti-CTLA4 checkpoint inhibitors for all tumor types, For Part 1 and Part 2 of Phase 1a (BJ-001 single agent treatment) both checkpoint inhibitor naïve or refractory/relapsed patients will be considered.\n* Patient who have diagnosis for which treatment with pembrolizumab to be enrolled. Patients previously treated with pembrolizumab and who have progressed are eligible. to be enrolled.\n\n  * Adequate hematologic function,\n  * Adequate hepatic function, defined by all of the following:\n  * Adequate renal function defined by estimated creatinine clearance ≥ 45 mL/min (Cockcroft and Gault formula\n  * ECOG Performance Status (PS) of 0-2.\n  * No history of any hematopoietic malignancy.\n  * No active or history of clinically significant autoimmune disease (as defined by previously requiring immunosuppressive therapy).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or nursing females.\n* Receipt of any investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug. Exceptions: Hormone replacement therapy, testosterone, or oral contraceptives (LHRH antagonists are allowed).\n* Patients previously treated with an anti PD-1/PD-L1 targeting agent who have had any prior history of immune-mediated pneumonitis, any immune-mediated toxicity of ≥ Grade 3,\n* Patients with a history of severe allergic or anaphylactic reactions to human mAb therapy or known hypersensitivity.\n* Patients with a history of pneumonitis, myocarditis, history of Stevens-Johnson syndrome or toxic epidermal necrolysis.\n* Patients who have undergone a bone marrow transplantation, solid organ transplantation, or stem cell transplant.\n* Patients with unresolved AEs > Grade 1 from prior anticancer therapy.\n* Patients who have received prior interferon or IL-2 therapy less than 4 weeks prior to enrollment.\n* Uncontrolled primary central nervous system (CNS) tumors or CNS metastases; based on screening.\n* Patients with active autoimmune disease or a documented medical history of autoimmune disease managed by replacement therapy.",
    "miscellaneous_criteria": ""
}